FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to	,
Section 16. Form 4 or Form 5 obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Labrucherie Gil M</u>						2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]									all applic Directo Officer	cable) or (give title	g Pers	on(s) to Iss 10% Ov Other (s	vner
(Last) (First) (Middle) C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH					3. Date of Earliest Transaction (Month/Day/Year) 08/13/2015								Λ	below) SN	/P & Ger	neral (below) Counsel		
(Street) SAN FRANCISCO CA 94158			4.	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Line) X Form filed by One Reporting Per Form filed by More than One Re Person											orting Perso	n			
(City)	(S	tate)	(Zip)																
		Tab	le I - No	n-Deri	vativ	e Se	curi	ties Ac	quired	, Dis	sposed o	of, or Be	neficia	ally	Owned				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Execution			3. Transa Code (4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a			and 5) Securition Benefici		es ally Following	Form (D) or	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock ⁽¹⁾ 08/13/2					3/2015	2015		М		33,333	A	\$6.9	98	38	,084		D		
Common Stock ⁽¹⁾ 08/13/2				3/2015	:015		S		33,333	B D \$10.8		39 ⁽²⁾	⁽²⁾ 4,751			D			
		-	Γable II ·								osed of, converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	Code (Ins				6. Date E Expiratio (Month/I	on Da		7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		D S	Price of erivative ecurity nstr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares	r					
Stock	\$6.98	08/13/2015			M			33,333	12/21/20	011	12/20/2015	Common	33,33	3	\$0.00	133,33	3	D	

Explanation of Responses:

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan for stock options scheduled to expire in 2015 as described in the Current Report on Form 8-K filed by Nektar Therapeutics on July 16, 2015.
- 2. This transaction was executed in multiple trades at prices ranging from \$10.40 to \$11.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Remarks:

Gilbert M. Labrucherie, Jr.

08/17/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.